Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,021 to 2,040 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma. | Biol Proced Online | 2022 | 35836132 | PubTator, text mining | PubMed |
| m6A-modified circRNAs: detections, mechanisms, and prospects in cancers. | Mol Med | 2022 | 35836125 | PubTator, text mining | PubMed |
| The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma. | Front Immunol | 2022 | 35833147 | PubTator, text mining | PubMed |
| Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery. | Nat Commun | 2022 | 35831314 | PubTator, text mining | PubMed |
| Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington's disease mice. | Cell Mol Life Sci | 2022 | 35819730 | PubTator, text mining | PubMed |
| Molecular Characterization and Clinical Relevance of N6-Methyladenosine Regulators in Metastatic Prostate Cancer. | Front Oncol | 2022 | 35814454 | PubTator, text mining | PubMed |
| Immune Infiltration and N(6)-Methyladenosine ncRNA Isoform Detection in Acute Lung Injury. | J Oncol | 2022 | 35813860 | PubTator, text mining | PubMed |
| Role of m6A modification in female infertility and reproductive system diseases. | Int J Biol Sci | 2022 | 35813486 | PubTator, text mining | PubMed |
| Integrative Analyses of m6A Regulators Identify that METTL3 is Associated with HPV Status and Immunosuppressive Microenvironment in HPV-related Cancers. | Int J Biol Sci | 2022 | 35813476 | PubTator, text mining | PubMed |
| N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma. | Front Cell Dev Biol | 2022 | 35813200 | PubTator, text mining | PubMed |
| m6A Regulator-Mediated RNA Methylation Modification Patterns Regulate the Immune Microenvironment in Osteoarthritis. | Front Genet | 2022 | 35812736 | PubTator, text mining | PubMed |
| Fear Stress During Pregnancy Affects Placental m6A-Modifying Enzyme Expression and Epigenetic Modification Levels. | Front Genet | 2022 | 35812725 | PubTator, text mining | PubMed |
| Role of m6A Methylation in the Occurrence and Development of Heart Failure. | Front Cardiovasc Med | 2022 | 35811741 | PubTator, text mining | PubMed |
| METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. | EBioMedicine | 2022 | 35810559 | PubTator, text mining | PubMed |
| Next RNA Therapeutics: The Mine of Non-Coding. | Int J Mol Sci | 2022 | 35806476 | PubTator, text mining | PubMed |
| Comprehensive Analysis of N6-Methyladenosine (m6A) Writers, Erasers, and Readers in Cervical Cancer. | Int J Mol Sci | 2022 | 35806168 | PubTator, text mining | PubMed |
| Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer. | Cancers (Basel) | 2022 | 35804965 | PubTator, text mining | PubMed |
| The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics. | Front Immunol | 2022 | 35799793 | PubTator, text mining | PubMed |
| Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration. | J Oncol | 2022 | 35799606 | PubTator, text mining | PubMed |
| ALKBH5 inhibits TNF-α-induced apoptosis of HUVECs through Bcl-2 pathway. | Open Med (Wars) | 2022 | 35799597 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=102